<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003116</url>
  </required_header>
  <id_info>
    <org_study_id>2019-000266-37</org_study_id>
    <nct_id>NCT04003116</nct_id>
  </id_info>
  <brief_title>Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE)</brief_title>
  <acronym>AIRE</acronym>
  <official_title>Randomized Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With Supplementary Oxygen in Patients With Intermediate-Risk Pulmonary Embolism (PE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of the treatment with supplementary oxygen&#xD;
      added to conventional anticoagulant treatment in patients with Intermediate-risk pulmonary&#xD;
      embolism.&#xD;
&#xD;
      The secondary objective is to evaluate the safety of the treatment with supplementary oxygen&#xD;
      added to conventional anticoagulant treatment in patients with Intermediate-risk pulmonary&#xD;
      embolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modification RV -LV 48h</measure>
    <time_frame>48 hours</time_frame>
    <description>Modification of the right ventricle (RV) to the left ventricle (LV) diameter ratio measured 48 hours after initiation of therapy in normotensive patients with intermediate-risk pulmonary embolism (PE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modification RV -LV 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Modification of the right ventricle (RV) to the left ventricle (LV) diameter ratio measured 7 days after initiation of therapy in normotensive patients with intermediate-risk pulmonary embolism (PE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Supplementary oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementary oxygen added to conventional anticoagulant treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen gas</intervention_name>
    <description>Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.</description>
    <arm_group_label>Supplementary oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed PE by multidetector computed tomographic pulmonary angiography (MDCT).&#xD;
&#xD;
          -  Disfunction of right ventricle (RV to left ventricle [LV] diameter ratio &gt;1.0 in the&#xD;
             apical 4-chamber view) in the echocardiogram performed in the first 12 hours after PE&#xD;
             diagnosis.&#xD;
&#xD;
          -  Signed and dated informed consent of the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years old.&#xD;
&#xD;
          -  Allergy to iodinated contrast.&#xD;
&#xD;
          -  Renal failure defined as a creatinine clearance less than 30 mL/min, according to the&#xD;
             Cockcroft-Gault formula.&#xD;
&#xD;
          -  Use of chronic oxygen therapy.&#xD;
&#xD;
          -  Hypercapnia (pCO2 &gt;50 mmHg at the time of diagnosis).&#xD;
&#xD;
          -  Technically inadequate basal echocardiography.&#xD;
&#xD;
          -  Contraindication to anticoagulant therapy.&#xD;
&#xD;
          -  Symptoms duration &gt;10 days.&#xD;
&#xD;
          -  Haemodynamic instability.&#xD;
&#xD;
          -  Participation in other clinical trial for PE treatment during the present clinical&#xD;
             trial.&#xD;
&#xD;
          -  Inability to use mask or nasal prongs.&#xD;
&#xD;
          -  Life expectancy less than 90 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jiménez</last_name>
    <role>Study Chair</role>
    <affiliation>IRYCIS, Alcala de Henares University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Jiménez, MD, PhD</last_name>
    <phone>+34669461858</phone>
    <email>djimenez.hrc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Araba</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Lobo</last_name>
    </contact>
    <investigator>
      <last_name>José Luis Lobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leyre Chasco</last_name>
    </contact>
    <investigator>
      <last_name>Leyre Chasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Moisés</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Moisés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Ruiz-Artacho</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Ruiz-Artacho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deisy Diana Barrios</last_name>
    </contact>
    <investigator>
      <last_name>Deisy Diana Barrios</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Jara-Palomares</last_name>
    </contact>
    <investigator>
      <last_name>Luis Jara-Palomares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel López-Reyes</last_name>
    </contact>
    <investigator>
      <last_name>Raquel López-Reyes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Spain</investigator_affiliation>
    <investigator_full_name>David Jimenez</investigator_full_name>
    <investigator_title>Pulmonary physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

